A renewed Strategic Plan

Uniting stakeholders to share knowledge, foster collaboration, enable solutions and to support the most critical issues, risks and challenges faced by the field

Increasing resources

Mobilizing new funding to support and grow the field of HIV vaccine research and development

Greater collaboration

Promoting more efficient, faster ways for researchers to share successes and failures and avoid duplication of efforts

News

New home for a renewed Enterprise

The HIV vaccine field has built considerable momentum in recent years with multiple efficacy-stage programmes underway and new vaccine concepts in the clinical pipeline. The range of opportunities and possibilities is matched by a growing sense of urgency that the field is underprepared for the complex challenges that remain. For three decades, the International AIDS […]

Upcoming event

HIV Vaccine R&D at the IAS Science Conference 2019

The IAS Conference on HIV Science is the world’s most influential meeting on HIV research and its applications. This biennial conference presents the critical advances in basic, clinical and operational research that moves science into policy and practice. Through its open and inclusive programme development, the meeting sets the gold standard of HIV research featuring highly diverse and cutting-edge studies.

HIV Vaccine research and development will be very much featured before and during the conference.

Timely topics

In 2012, the Enterprise launched Timely Topics in HIV Vaccines, a strategy series convening experts as rapidly as possible to analyze, address, and respond to unresolved and emerging priority issues in the field. Through an open call for proposals, the Enterprise is working to identify the most important strategic needs of the field and sponsoring think tanks, meetings, forums and other events to tackle these issues.

Newsletter

Sign up to receive the latest news of the Vaccine Enterprise and occasional information related to IAS activities related to vaccine research and development (Please read our Privacy Policy)